Evidence map›Paper›PMID 37184125›Full record

ArticleCancer medicine2023

Downregulation of miR-100-5p in cancer-associated fibroblast-derived exosomes facilitates lymphangiogenesis in esophageal squamous cell carcinoma.

Chao Chen, Chenbo Yang, Xiangyu Tian, Yinghao Liang, Shuaiyuan Wang, Xiaoqian Wang, Yuwei Shou, Hui Li, Qiankun Xiao, Jiao Shu and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Exosomes in esophageal cancer: function and therapeutic prospects.Medical oncology (Northwood, London, England) · 2024
    Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Chao ChenSchool of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.ORCID 0000-0002-6259-3361
Chenbo YangHenan Key Laboratory of Tumor Pathology, Zhengzhou University, Zhengzhou, China.
Xiangyu TianHenan Key Laboratory of Tumor Pathology, Zhengzhou University, Zhengzhou, China.
Yinghao LiangHenan Key Laboratory of Tumor Pathology, Zhengzhou University, Zhengzhou, China.
Shuaiyuan WangHenan Key Laboratory of Tumor Pathology, Zhengzhou University, Zhengzhou, China.
Xiaoqian WangHenan Key Laboratory of Tumor Pathology, Zhengzhou University, Zhengzhou, China.
Yuwei ShouHenan Key Laboratory of Tumor Pathology, Zhengzhou University, Zhengzhou, China.
Hui LiHenan Key Laboratory of Tumor Pathology, Zhengzhou University, Zhengzhou, China.
Qiankun XiaoHenan Key Laboratory of Tumor Pathology, Zhengzhou University, Zhengzhou, China.
Jiao ShuHenan Key Laboratory of Tumor Pathology, Zhengzhou University, Zhengzhou, China.
Miaomiao SunHenan Key Laboratory of Tumor Pathology, Zhengzhou University, Zhengzhou, China.
Kuisheng ChenSchool of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.ORCID 0000-0002-0500-5543
Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEsophageal squamous cell carcinoma (ESCC), an aggressive gastrointestinal tumor, often has high early lymphatic metastatic potential. Cancer-associated fibroblasts (CAFs) are primary components in tumor microenvironment (TME), and the impact of CAFs and its derived exosomes on lymphangiogenesis remains elusive. MATERIALS AND

methodsCAFs and the microlymphatic vessel density (MLVD) in ESCC was examined. Exosomes were extracted from primary normal fibroblast (NFs) and CAFs. Subsequently, tumor-associated lymphatic endothelial cells (TLECs) were treated with these exosomes, and the effect on their biological behavior was examined. miR-100-5p was selected as the target miRNA, and its effect on TLECs was examined. The target of miR-100-5p was predicted and confirmed. Subsequently, IGF1R, PI3K, AKT, and p-AKT expression in TLECs and tumors treated with exosomes and miR-100-5p were examined.

resultsA large number of CAFs and microlymphatic vessels were present in ESCC, leading to a poor prognosis. CAF-derived exosomes promoted proliferation, migration, invasion, and tube formation in TLECs. Further, they also enhanced lymphangiogenesis in ESCC xenografts. miR-100-5p levels were significantly lower in CAF-derived exosomes than in NF-derived exosomes. miR-100-5p inhibited proliferation, migration, invasion, and tube formation in TLECs. Further, miR-100-5p inhibited lymphangiogenesis in ESCC xenografts. Mechanistic studies revealed that this inhibition was mediated by the miR-100-5p-induced inhibition of IGF1R/PI3K/AKT axis.

conclusionTaken together, our study demonstrates that CAF-derived exosomes with decreased miR-100-5p levels exhibit pro-lymphangiogenesis capacity, suggesting a possibility of targeting IGF1R/PI3K/AKT axis as a strategy to inhibit lymphatic metastasis in ESCC.

Indexed as

Cancer-Associated FibroblastsEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaExosomesMicroRNAsCell Line, TumorCell MovementCell ProliferationDown-RegulationEndothelial CellsGene Expression Regulation, NeoplasticHumansLymphangiogenesisPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTumor MicroenvironmentMicroRNAsMIRN100 microRNA, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktcancer-associated fibroblastsesophageal squamous cell carcinomaexosomeslymphangiogenesismiR-100-5p

Identifiers

PMID37184125
PMCPMC10358253
OpenAlexW4376629905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.